Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.49 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.49 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP3 | P08254 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9041685 | 0.89 | HDAC1 (0.58) | TDP1HDAC2HDAC8HDAC6CA12 | |
| SCHEMBL8909859 | 0.87 | MAPT (0.58) | HDAC2HDAC8HDAC6HDAC3HDAC4 | |
| SCHEMBL10015891 | 0.83 | KEAP1 (0.59) | KEAP1ALDH1A1FFAR1TDP1L3MBTL1 | |
| SCHEMBL13651467 | 0.81 | ALOX5 (0.50) | KEAP1ALDH1A1FFAR1TDP1L3MBTL1 | |
| SCHEMBL497371 | 0.81 | KEAP1 (0.73) | KEAP1ALDH1A1FFAR1TDP1L3MBTL1 | |
| Fosfonet SCHEMBL413303 | 0.80 | TSHR (0.58) | KEAP1FFAR1TDP1ANPEPERAP1 | |
| SCHEMBL4940168 | 0.80 | CES1 (0.52) | ALDH1A1TDP1L3MBTL1ANPEPHDAC8 | |
| SCHEMBL11400661 | 0.80 | PLAAT3 (0.48) | ALDH1A1FFAR1HDAC1SMN1; SMN2 | |
| SCHEMBL11560528 | 0.80 | TAAR1 (0.46) | ALDH1A1TDP1L3MBTL1HDAC2HDAC8 | |
| SCHEMBL107423 | 0.79 | KEAP1 (0.70) | KEAP1ALDH1A1FFAR1TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116947724-A | Synthesis method of latanoprost | 广州楷石医药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-2669280-B1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO (JP) | 2016-04-27 | — | — | EP | disclosed |
| US-9150537-B2 | Bicyclic compound and use thereof for medical purposes | ONO PHARMACEUTICAL CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2495235-B1 | Process for the synthesis of prostaglandins and intermediates thereof | NEWCHEM S P A (IT) | 2015-08-05 | — | — | EP | disclosed |
| EP-2669280-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO Pharmaceutical Co., Ltd. (JP) | 2013-12-04 | — | — | EP | disclosed |
| US-20130310438-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-21 | — | — | US | disclosed |
| EP-2496553-A1 | A NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | Biocon Limited (IN) | 2012-09-12 | — | — | EP | disclosed |
| EP-2495235-A1 | Process for the synthesis of prostaglandins and intermediates thereof | Newchem S.p.A. (IT) | 2012-09-05 | — | — | EP | disclosed |
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | ASWATHANARAYANAPPA CHANDRASHEKAR (IN) | 2012-08-16 | — | — | US | disclosed |
| EP-2311820-A1 | Process for the purification of latanoprost by HPLC | Resolution Chemicals Limited (GB) | 2011-04-20 | — | — | EP | disclosed |
| US-4102888-A | VASODILATORS, ANTITHROMBITIC | MERCK & CO., INC. (US) | 1978-07-25 | — | — | US | disclosed |
| US-4100355-A | 8β,12α-PGE2 -type compounds | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097675-A | 8β, 12α, 15β-PGF2α Compounds | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
| US-4096342-A | 8β,12α,15β-PGE2 compounds | THE UPJOHN COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
| US-4095036-A | 8β,12α,15β-PGF2 β Compounds | THE UPJOHN COMPANY (US) | 1978-06-13 | — | — | US | disclosed |
| US-4084063-A | PROSTAGLANDINS; ANTIULCER AGENTS, ANTICOAGULANTS, OXYTOCICS, DECONGESTANTS | THE UPJOHN COMPANY (US) | 1978-04-11 | — | — | US | disclosed |
| US-4059587-A | 8-AZA-9-OXO-11-THIA-PROSTANOIC ACID DERIVATIVES; VASODILATORS, ANTICLOTTING, REGULATORS OF IMMUNE RESPONSE | MERCK & CO., INC. (US) | 1977-11-22 | — | — | US | disclosed |
| US-3987087-A | ANTI-ULCER, NASAL PATENCY, WOUND HEALING, LABOR INDUCEMENT | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3987085-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1976-10-19 | — | — | US | disclosed |
| US-3931279-A | 5-Oxa prostaglandin F2.sub.α analogs | THE UPJOHN COMPANY (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120209011-A1 | NOVEL PROCESS FOR THE PREPARATION OF PROSTAGLANDINS AND INTERMEDIATES THEREOF | PTGER3, CBR3, PTGES3 | KEAP1 287/4885ALDH1A1 994/4885FFAR1 291/4885 |
| US-20130310438-A1 | BICYCLIC COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | PDE3A, PRKG1, PDE2A | KEAP1 78/4885ALDH1A1 1196/4885FFAR1 2397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.